TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
TEL AVIV - Xenetic Biosciences, Inc. (NASDAQ:XBIO), a biopharmaceutical company specializing in immuno-oncology technologies with a current market capitalization of $5.21 million, has announced a new clinical study of its systemic DNase I candidate, XBIO-015, in collaboration with PeriNess Ltd. The study will focus on patients with relapsed/refractory osteosarcoma and Ewing sarcoma at the Tel-Aviv Sourasky Medical Center. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 7.37, positioning it well for clinical development initiatives.
The exploratory study, led by Prof. Ronit Elhasid of the Dana-Dwek Children’s Hospital, will assess the safety, tolerability, and efficacy of XBIO-015 in combination with chemotherapy. The primary goal is to evaluate the treatment’s safety, while secondary objectives include measuring the objective response rate and progression-free survival in patients. The study also aims to analyze the response of biomarkers. InvestingPro analysis shows the company holds more cash than debt, providing financial flexibility for its research programs.
Xenetic’s proprietary recombinant DNase I is an enzyme designed to digest neutrophil extracellular traps (NETs) within the tumor microenvironment. NETs have been identified as a factor in the progression of several cancers, including pediatric sarcomas, where they are associated with a poor prognosis.
James Parslow, Interim CEO and CFO of Xenetic, emphasized the company’s commitment to expanding clinical data for its DNase program. This study is part of a broader strategy to evaluate the potential of XBIO-015 in combination with various treatments across different oncology indications.
Previously, in December 2024, Xenetic and PeriNess entered into an agreement to conduct studies on recombinant DNase as an adjunctive treatment for pancreatic carcinoma and other advanced solid tumors in Israel.
This clinical study announcement is based on a press release statement and should be considered in the context of the risks and uncertainties that may affect the future performance and results of Xenetic Biosciences. The stock currently trades below book value with a P/B ratio of 0.87, and InvestingPro analysis suggests the shares may be undervalued. Investors should note the company’s high beta of 2.18, indicating significant stock price volatility compared to the broader market. For comprehensive analysis and additional insights, including 8 more ProTips, visit InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.